Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Clinical Study Evaluating the Safety, Tolerability, Efficacy, and Pharmacokinetic Characteristics of BY101298 Combined with Radiotherapy in Patients with Malignant Solid Tumors

NCT06524804 is registered in ClinicalTrials.gov with Chengdu Baiyu Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06524804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06524804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Clinical Study Evaluating the Safety, Tolerability, Efficacy, and Pharmacokinetic Characteristics of BY101298 Combined with Radiotherapy in Patients with Malignant Solid Tumors
Lead sponsor
Chengdu Baiyu Pharmaceutical Co., Ltd.
Phase
Phase 1/2
Overall status
Terminated
Start date
May 15, 2024
Completion date
October 18, 2024
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, adult